JPS62258320A - 内服用新規医薬製剤 - Google Patents
内服用新規医薬製剤Info
- Publication number
- JPS62258320A JPS62258320A JP62108762A JP10876287A JPS62258320A JP S62258320 A JPS62258320 A JP S62258320A JP 62108762 A JP62108762 A JP 62108762A JP 10876287 A JP10876287 A JP 10876287A JP S62258320 A JPS62258320 A JP S62258320A
- Authority
- JP
- Japan
- Prior art keywords
- omeprazole
- alkali
- salt
- core portion
- intermediate coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 100
- 229960000381 omeprazole Drugs 0.000 claims abstract description 97
- 239000010410 layer Substances 0.000 claims abstract description 42
- 238000000576 coating method Methods 0.000 claims abstract description 38
- 239000011248 coating agent Substances 0.000 claims abstract description 33
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- 239000011247 coating layer Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000000395 magnesium oxide Substances 0.000 claims abstract description 8
- 150000001447 alkali salts Chemical class 0.000 claims abstract description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 60
- 238000009472 formulation Methods 0.000 claims description 37
- 239000002702 enteric coating Substances 0.000 claims description 36
- 238000009505 enteric coating Methods 0.000 claims description 36
- 239000002552 dosage form Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000003513 alkali Substances 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 7
- 239000004014 plasticizer Substances 0.000 claims description 7
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 6
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 6
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 6
- 239000000347 magnesium hydroxide Substances 0.000 claims description 6
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 3
- 159000000007 calcium salts Chemical class 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims description 3
- 239000001095 magnesium carbonate Substances 0.000 claims description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims description 3
- 159000000003 magnesium salts Chemical class 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims 1
- 229910052782 aluminium Inorganic materials 0.000 claims 1
- 150000003863 ammonium salts Chemical class 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 229940063559 methacrylic acid Drugs 0.000 claims 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 claims 1
- 229920000642 polymer Polymers 0.000 abstract description 15
- 230000002496 gastric effect Effects 0.000 abstract description 9
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 4
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 3
- 230000000968 intestinal effect Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 210000004211 gastric acid Anatomy 0.000 abstract description 2
- 239000008188 pellet Substances 0.000 description 52
- 239000003826 tablet Substances 0.000 description 26
- 238000003860 storage Methods 0.000 description 23
- 230000000052 comparative effect Effects 0.000 description 19
- 239000000243 solution Substances 0.000 description 18
- 238000000926 separation method Methods 0.000 description 10
- 239000007903 gelatin capsule Substances 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 9
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- -1 hydrogen ions Chemical class 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000000354 decomposition reaction Methods 0.000 description 6
- 210000004051 gastric juice Anatomy 0.000 description 6
- 230000007774 longterm Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000006186 oral dosage form Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 229920001688 coating polymer Polymers 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000002662 enteric coated tablet Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001458 anti-acid effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000337 buffer salt Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- PPQREHKVAOVYBT-UHFFFAOYSA-H dialuminum;tricarbonate Chemical compound [Al+3].[Al+3].[O-]C([O-])=O.[O-]C([O-])=O.[O-]C([O-])=O PPQREHKVAOVYBT-UHFFFAOYSA-H 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000027119 gastric acid secretion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001087 glyceryl triacetate Substances 0.000 description 2
- 235000013773 glyceryl triacetate Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000002681 magnesium compounds Chemical class 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- RRFCKCAQHRITRG-UHFFFAOYSA-N sodium;5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]benzimidazol-3-ide;hydrate Chemical compound O.[Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RRFCKCAQHRITRG-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229960002622 triacetin Drugs 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 101100042788 Caenorhabditis elegans him-1 gene Proteins 0.000 description 1
- 101100074836 Caenorhabditis elegans lin-22 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- YUXIBTJKHLUKBD-UHFFFAOYSA-N Dibutyl succinate Chemical compound CCCCOC(=O)CCC(=O)OCCCC YUXIBTJKHLUKBD-UHFFFAOYSA-N 0.000 description 1
- 101100101065 Dictyostelium discoideum tsuA gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940118662 aluminum carbonate Drugs 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 239000000292 calcium oxide Substances 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000004490 capsule suspension Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229960002097 dibutylsuccinate Drugs 0.000 description 1
- CRVGKGJPQYZRPT-UHFFFAOYSA-N diethylamino acetate Chemical compound CCN(CC)OC(C)=O CRVGKGJPQYZRPT-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 159000000011 group IA salts Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- MQEUGMWHWPYFDD-UHFFFAOYSA-N magnesium;6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1h-benzimidazole Chemical class [Mg].N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C MQEUGMWHWPYFDD-UHFFFAOYSA-N 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- FYFFGSSZFBZTAH-UHFFFAOYSA-N methylaminomethanetriol Chemical compound CNC(O)(O)O FYFFGSSZFBZTAH-UHFFFAOYSA-N 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229940075065 polyvinyl acetate Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08610572A GB2189698A (en) | 1986-04-30 | 1986-04-30 | Coated omeprazole tablets |
| GB8610572 | 1986-04-30 | ||
| SG154294A SG154294G (en) | 1986-04-30 | 1994-10-21 | New pharmaceutical preparation for oral use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3355985A Division JP2740993B2 (ja) | 1986-04-30 | 1991-12-20 | 内服用新規医薬製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62258320A true JPS62258320A (ja) | 1987-11-10 |
| JP5069807B2 JP5069807B2 (el) | 1993-10-01 |
Family
ID=26290693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62108762A Granted JPS62258320A (ja) | 1986-04-30 | 1987-04-30 | 内服用新規医薬製剤 |
| JP3355985A Expired - Lifetime JP2740993B2 (ja) | 1986-04-30 | 1991-12-20 | 内服用新規医薬製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3355985A Expired - Lifetime JP2740993B2 (ja) | 1986-04-30 | 1991-12-20 | 内服用新規医薬製剤 |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US4786505A (el) |
| EP (3) | EP0496437B1 (el) |
| JP (2) | JPS62258320A (el) |
| KR (1) | KR910004579B1 (el) |
| CN (1) | CN1020852C (el) |
| AR (1) | AR240250A1 (el) |
| AT (3) | ATE184482T1 (el) |
| CA (1) | CA1292693C (el) |
| CY (1) | CY1810A (el) |
| DD (1) | DD273197A5 (el) |
| DE (3) | DE247983T1 (el) |
| DK (1) | DK169988B1 (el) |
| DZ (1) | DZ1077A1 (el) |
| ES (3) | ES2135443T3 (el) |
| FI (1) | FI90393C (el) |
| GB (1) | GB2189698A (el) |
| GR (4) | GR890300058T1 (el) |
| HK (2) | HK135294A (el) |
| HR (1) | HRP920854B1 (el) |
| HU (1) | HU196708B (el) |
| IE (1) | IE61416B1 (el) |
| IL (1) | IL82911A (el) |
| IS (1) | IS1917B (el) |
| LT (1) | LT3699B (el) |
| LV (2) | LV10357B (el) |
| NO (1) | NO174239C (el) |
| NZ (1) | NZ220096A (el) |
| PH (1) | PH25701A (el) |
| PL (1) | PL151631B1 (el) |
| PT (1) | PT84785B (el) |
| RU (2) | RU1820837C (el) |
| SG (1) | SG154294G (el) |
| SI (1) | SI8710681A8 (el) |
| YU (1) | YU46192B (el) |
| ZA (1) | ZA872378B (el) |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01290628A (ja) * | 1988-05-18 | 1989-11-22 | Eisai Co Ltd | 酸不安定化合物の内服用製剤 |
| JPH0222225A (ja) * | 1988-07-11 | 1990-01-25 | Eisai Co Ltd | 胃酸分泌抑制剤含有固型製剤 |
| JPH04288015A (ja) * | 1990-10-11 | 1992-10-13 | Merck & Co Inc | 消化性潰瘍の治療 |
| JPH072648A (ja) * | 1993-04-23 | 1995-01-06 | Ciba Geigy Ag | 徐放性ドラッグデリバリーデバイス |
| JPH11501951A (ja) * | 1996-01-08 | 1999-02-16 | アストラ・アクチエボラーグ | プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形 |
| JP2000514051A (ja) * | 1996-06-28 | 2000-10-24 | クリンゲ ファーマ ジーエムビーエイチ | ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法 |
| JP2001525366A (ja) * | 1997-12-08 | 2001-12-11 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 酸不安定な活性化合物を含有する新規の投与形 |
| JP2002500665A (ja) * | 1997-05-28 | 2002-01-08 | アストラ・アクチエボラーグ | オメプラゾール製剤 |
| JP2002234842A (ja) * | 2001-02-09 | 2002-08-23 | Kyowa Yakuhin Kogyo Kk | 内服腸溶性製剤 |
| JP2003516342A (ja) * | 1999-12-09 | 2003-05-13 | ラティオファルム ゲー・エム・ベー・ハー | ベンズイミダゾールを含む安定な医薬品およびその製造方法 |
| JP2004155773A (ja) * | 2002-10-16 | 2004-06-03 | Takeda Chem Ind Ltd | 安定な固形製剤 |
| US6780882B2 (en) | 1996-01-04 | 2004-08-24 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| JP2005521693A (ja) * | 2002-03-05 | 2005-07-21 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールのアルキルアンモニウム塩 |
| JP2006528198A (ja) * | 2003-07-23 | 2006-12-14 | ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ | 酸不安定な医薬組成物の即時放出製剤 |
| EP1736144A2 (en) | 1998-05-18 | 2006-12-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| US7220762B1 (en) | 1999-10-20 | 2007-05-22 | Eisai R&D Management Co., Ltd. | Methods for stabilizing benzimidazole compounds |
| JP2007517038A (ja) * | 2003-12-30 | 2007-06-28 | ドクター レディズ ラボラトリーズ リミテッド | 薬学的組成物 |
| WO2007074856A1 (ja) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | 口腔内崩壊性固形製剤の製造法 |
| JP2009504709A (ja) * | 2005-08-15 | 2009-02-05 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸に不安定な薬剤のための制御放出性医薬組成物 |
| JP2010180225A (ja) * | 2002-10-16 | 2010-08-19 | Takeda Chem Ind Ltd | 安定な固形製剤 |
| JP2012505884A (ja) * | 2008-10-20 | 2012-03-08 | ケージー アクキュイシチオン エルエルシー | 抗血小板薬と腸溶性コーティング酸阻害剤とを含む経口剤形 |
| USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
Families Citing this family (332)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| US6749864B2 (en) * | 1986-02-13 | 2004-06-15 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| GB8724763D0 (en) * | 1987-10-22 | 1987-11-25 | Aps Research Ltd | Sustained-release formulations |
| US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
| US5006346A (en) * | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
| US5202128A (en) * | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
| US5540945A (en) * | 1989-05-11 | 1996-07-30 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines |
| CA2032475C (en) * | 1989-05-11 | 1997-12-30 | Heiji Ikushima | Pharmaceutical preparations for oral administration that are adapted to release the drug at appropriate sites in the intestines |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| PH27186A (en) * | 1989-09-07 | 1993-04-16 | Ciba Geigy Ag | Double-coated granules of disodium pamidronate |
| US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| KR930000861B1 (ko) * | 1990-02-27 | 1993-02-08 | 한미약품공업 주식회사 | 오메프라졸 직장투여 조성물 |
| US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
| US5232706A (en) * | 1990-12-31 | 1993-08-03 | Esteve Quimica, S.A. | Oral pharmaceutical preparation containing omeprazol |
| YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
| ATE156707T1 (de) * | 1991-06-21 | 1997-08-15 | Ilsan Ilac Ve Hammaddeleri San | Neues galenisches verfahren für omeprazol enthaltende pellets |
| US6764697B1 (en) * | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
| HU9202318D0 (en) * | 1991-07-22 | 1992-10-28 | Bristol Myers Squibb Co | Method for preparing medical preparatives containing didesoxi-purine nucleoside |
| WO1993009785A1 (en) * | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
| US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5472712A (en) * | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US7070806B2 (en) * | 1992-01-27 | 2006-07-04 | Purdue Pharma Lp | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
| WO1994002140A1 (en) * | 1992-07-17 | 1994-02-03 | Astra Aktiebolag | Pharmaceutical composition containing antiulcer agent |
| SE9301489D0 (sv) * | 1993-04-30 | 1993-04-30 | Ab Astra | Veterinary composition |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| US6875872B1 (en) | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| SE9302395D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | New pharmaceutical formulation |
| TW397686B (en) * | 1993-08-11 | 2000-07-11 | Takeda Chemical Industries Ltd | Antacid compositions and pharmaceutical compositions |
| TW280770B (el) | 1993-10-15 | 1996-07-11 | Takeda Pharm Industry Co Ltd | |
| CA2180535C (en) * | 1994-01-05 | 2004-03-23 | Lindberg, Per Lennart | A method for treatment of psoriasis, by omeprazole or related compounds |
| DK0746310T3 (da) * | 1994-02-23 | 1999-08-02 | Bm Res As | Præparat med styret afgivelse |
| BR9508261A (pt) * | 1994-07-08 | 1997-12-23 | Astra Ab | Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal |
| ATE414509T1 (de) * | 1994-07-08 | 2008-12-15 | Astrazeneca Ab | Aus vielen einzeleinheiten zusammengesetzte tablettierte dosisform |
| SE9402431D0 (sv) * | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| SE504459C2 (sv) * | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| AU694818B2 (en) * | 1994-11-21 | 1998-07-30 | Shell Internationale Research Maatschappij B.V. | Bitumen compositions |
| ES2094694B1 (es) * | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion. |
| SE9500422D0 (sv) * | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| CR5278A (es) | 1995-03-24 | 1996-07-04 | Lilly Co Eli | Formulacion oral de 2-metil-tieno-benzodiacepina |
| GB2316342B (en) * | 1995-05-09 | 2000-01-12 | Colorcon Ltd | Electrostatic coating |
| CA2220506C (en) * | 1995-05-09 | 2008-01-08 | Colorcon Limited | Powder coating composition for electrostatic coating of pharmaceutical substrates |
| US7008668B2 (en) | 1995-05-09 | 2006-03-07 | Phoqus Pharmaceuticals Limited | Powder coating composition for electrostatic coating of pharmaceutical substrates |
| US5824339A (en) * | 1995-09-08 | 1998-10-20 | Takeda Chemical Industries, Ltd | Effervescent composition and its production |
| PL186605B1 (pl) * | 1995-09-21 | 2004-01-30 | Pharma Pass Llc | Tabletka lub mikrotabletka zawierająca rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol oraz sposób wytwarzania tabletek lub mikrotabletek zawierających rdzeń posiadający jako kwasolabilny składnik aktywny omeprazol |
| US6645988B2 (en) | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| SE9600072D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
| SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| SE9600070D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| US6623759B2 (en) | 1996-06-28 | 2003-09-23 | Astrazeneca Ab | Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof |
| EP0941074B1 (en) * | 1996-11-06 | 2004-07-21 | Wockhardt Europe Limited | Delayed delivery system for acid-sensitive drugs |
| DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
| GB9623634D0 (en) | 1996-11-13 | 1997-01-08 | Bpsi Holdings Inc | Method and apparatus for the coating of substrates for pharmaceutical use |
| AU5446798A (en) * | 1996-11-27 | 1998-06-22 | Procter & Gamble Company, The | Compositions and methods for the treatment of gastrointestinal disorders |
| SE510666C2 (sv) * | 1996-12-20 | 1999-06-14 | Astra Ab | Nya Kristallmodifikationer |
| US5891474A (en) * | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
| AU7375598A (en) * | 1997-05-09 | 1998-11-27 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
| GB9710800D0 (en) * | 1997-05-23 | 1997-07-23 | Cipla Limited | Pharmaceutical composition and method of preparing it |
| SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
| SE510643C2 (sv) | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| SE9702533D0 (sv) | 1997-07-01 | 1997-07-01 | Astra Ab | New oral formulation |
| SI9700186B (sl) * | 1997-07-14 | 2006-10-31 | Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. | Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin |
| ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
| US6296876B1 (en) * | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
| US20050244497A1 (en) * | 1997-11-05 | 2005-11-03 | Wockhardt Limited | Delayed delivery system for acid-sensitive drugs |
| US6174548B1 (en) * | 1998-08-28 | 2001-01-16 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| US6096340A (en) * | 1997-11-14 | 2000-08-01 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| DE19752843C2 (de) * | 1997-11-28 | 2003-01-09 | Byk Gulden Lomberg Chem Fab | Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol |
| SE9704870D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| FR2774288B1 (fr) | 1998-01-30 | 2001-09-07 | Ethypharm Sa | Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques |
| DK173431B1 (da) | 1998-03-20 | 2000-10-23 | Gea Farmaceutisk Fabrik As | Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs |
| KR100627614B1 (ko) | 1998-04-20 | 2006-09-25 | 에자이 가부시키가이샤 | 안정화된 벤즈이미다졸계 화합물 함유 조성물로 이루어지는 의약제제 |
| JP4127740B2 (ja) * | 1998-04-20 | 2008-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化したベンズイミダゾール系化合物含有組成物 |
| US7122207B2 (en) * | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| UA69413C2 (uk) | 1998-05-22 | 2004-09-15 | Брістол-Майерс Сквібб Компані | Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції |
| ZA9810765B (en) * | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
| UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
| US7041313B1 (en) * | 1998-08-12 | 2006-05-09 | Altana Pharma Ag | Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles |
| US7094426B2 (en) * | 1998-08-27 | 2006-08-22 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
| US6733778B1 (en) * | 1999-08-27 | 2004-05-11 | Andrx Pharmaceuticals, Inc. | Omeprazole formulation |
| KR100314351B1 (ko) * | 1998-10-01 | 2002-03-21 | 민경윤 | 벤즈이미다졸유도체의장용성제제및그제조방법 |
| SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
| ES2222754T3 (es) * | 1998-11-18 | 2005-02-01 | Astrazeneca Ab | Procedimiento quimico mejorado, y formulacion farmaceutica. |
| TWI242000B (en) | 1998-12-10 | 2005-10-21 | Univ Southern California | Reversible aqueous pH sensitive lipidizing reagents, compositions and methods of use |
| SE9900274D0 (sv) | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
| US6197329B1 (en) | 1999-05-03 | 2001-03-06 | Drugtech Corporation | Anti-nausea compositions and methods |
| IL130602A0 (en) | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
| US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
| US6262086B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6312723B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Pharmaceutical unit dosage form |
| US6326384B1 (en) | 1999-08-26 | 2001-12-04 | Robert R. Whittle | Dry blend pharmaceutical unit dosage form |
| US6268385B1 (en) | 1999-08-26 | 2001-07-31 | Robert R. Whittle | Dry blend pharmaceutical formulations |
| US6780880B1 (en) | 1999-08-26 | 2004-08-24 | Robert R. Whittle | FT-Raman spectroscopic measurement |
| US6262085B1 (en) | 1999-08-26 | 2001-07-17 | Robert R. Whittle | Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US6312712B1 (en) | 1999-08-26 | 2001-11-06 | Robert R. Whittle | Method of improving bioavailability |
| ES2168043B1 (es) | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
| US6228400B1 (en) * | 1999-09-28 | 2001-05-08 | Carlsbad Technology, Inc. | Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same |
| US20040191276A1 (en) * | 1999-11-30 | 2004-09-30 | Cutispharma, Inc. | Compositions and kits for compounding pharmaceuticals |
| GB0002305D0 (en) | 2000-02-01 | 2000-03-22 | Phoqus Limited | Power material for electrostatic application |
| SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| SE0000773D0 (sv) * | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| US6242003B1 (en) * | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| US6306435B1 (en) * | 2000-06-26 | 2001-10-23 | Yung Shin Pharmaceutical Industrial Co. Ltd. | Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same |
| US6544556B1 (en) | 2000-09-11 | 2003-04-08 | Andrx Corporation | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| AU2001296908A1 (en) * | 2000-09-29 | 2002-04-08 | Geneva Pharmaceuticals, Inc. | Proton pump inhibitor formulation |
| IT1319655B1 (it) | 2000-11-15 | 2003-10-23 | Eurand Int | Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione. |
| SI20720A (sl) * | 2000-11-20 | 2002-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nov farmacevtski pripravek v obliki celuloznih kapsul uporaben za derivate benzimidazola |
| US6749867B2 (en) * | 2000-11-29 | 2004-06-15 | Joseph R. Robinson | Delivery system for omeprazole and its salts |
| US20020192299A1 (en) * | 2000-12-28 | 2002-12-19 | Rajneesh Taneja | Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| SE0100822D0 (sv) * | 2001-03-09 | 2001-03-09 | Astrazeneca Ab | Method II to obtain microparticles |
| CA2440588C (en) * | 2001-03-13 | 2010-02-09 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
| US20060127474A1 (en) * | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| CA2448927C (en) * | 2001-05-30 | 2011-08-09 | Euro-Celtique, S.A. | Pharmaceutical composition |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| ES2348710T5 (es) * | 2001-06-01 | 2014-02-17 | Pozen, Inc. | Composiciones farmacéuticas para el suministro coordinado de NSAID |
| SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| US20030235628A1 (en) * | 2001-09-19 | 2003-12-25 | Rajneesh Taneja | Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments |
| US20040062804A1 (en) | 2001-09-28 | 2004-04-01 | Der-Yang Lee | Modified release dosage forms |
| PT1459737E (pt) | 2001-10-17 | 2012-11-26 | Takeda Pharmaceutical | Grânulos contendo um composto químico instável em meio ácido em concentração elevada |
| IL146462A (en) * | 2001-11-13 | 2015-02-26 | Lycored Bio Ltd | Prolonged-release preparations containing as an active compound and analapaxin hydrochloride |
| ES2198195B1 (es) * | 2001-12-18 | 2004-10-01 | Laboratorios Del Dr. Esteve, S.A. | Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido. |
| US20040006111A1 (en) * | 2002-01-25 | 2004-01-08 | Kenneth Widder | Transmucosal delivery of proton pump inhibitors |
| US7245963B2 (en) * | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| US8209006B2 (en) * | 2002-03-07 | 2012-06-26 | Vgx Pharmaceuticals, Inc. | Constant current electroporation device and methods of use |
| US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| AU2003209534A1 (en) * | 2002-03-08 | 2003-09-22 | Bakulesh Mafatlal Khamar | The method of treating tuberculosis |
| US20030180358A1 (en) * | 2002-03-25 | 2003-09-25 | Stumberger Walter William | System and method for affecting the pH state of the contents of the distal bowel in mammals |
| CA2477841A1 (en) * | 2002-03-28 | 2003-10-09 | Astrazeneca Ab | Method of use |
| US20040005362A1 (en) * | 2002-07-03 | 2004-01-08 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| US20040082618A1 (en) * | 2002-07-03 | 2004-04-29 | Rajneesh Taneja | Liquid dosage forms of acid labile drugs |
| BR0313173A (pt) * | 2002-08-02 | 2007-07-17 | Ratiopharm Gmbh | preparação farmacêutica que contém um composto de benzimidazol misto com celulose microcristalina, método para sua preparação, bem como uso da dita celulose microcristalina |
| US20040028737A1 (en) * | 2002-08-12 | 2004-02-12 | Kopran Research Laboratories Limited | Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same |
| US20050191353A1 (en) * | 2002-08-16 | 2005-09-01 | Amit Krishna Antarkar | Process for manufacture of stable oral multiple unit pharmaceutical composition containing benzimidazoles |
| MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| US6893660B2 (en) * | 2002-11-21 | 2005-05-17 | Andrx Pharmaceuticals, Inc. | Stable pharmaceutical compositions without a stabilizer |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| JP2006513239A (ja) * | 2002-12-23 | 2006-04-20 | セルテック アメリカズ， インコーポレイテッド | 酸不安定性薬剤含有組成物 |
| WO2004066924A2 (en) * | 2003-01-24 | 2004-08-12 | Andrx Labs Llc | Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid |
| US20040146558A1 (en) * | 2003-01-28 | 2004-07-29 | Kyowa Pharmaceutical Co., Ltd. | Oral enteric-coated preparation |
| US8449911B2 (en) | 2003-03-12 | 2013-05-28 | Takeda Pharmaceutical Company Limited | Drug composition having active ingredient adhered at high concentration to spherical core |
| US20040185092A1 (en) * | 2003-03-18 | 2004-09-23 | Yih Ming Hsiao | Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use |
| TW200503783A (en) * | 2003-04-11 | 2005-02-01 | Altana Pharma Ag | Oral pharmaceutical preparation for proton pump antagonists |
| WO2004093875A1 (en) * | 2003-04-22 | 2004-11-04 | Dr. Reddy's Laboratories Limited | Oral pharmaceutical formulations comprising acid-labile active ingredients and a water-soluble sugar derivate, use thereof and the suitable process for manufacturing these |
| ES2234393B2 (es) * | 2003-04-29 | 2006-09-01 | Laboratorios Belmac, S.A. | "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido". |
| CL2004000983A1 (es) * | 2003-05-08 | 2005-03-04 | Altana Pharma Ag | Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y |
| PE20050150A1 (es) * | 2003-05-08 | 2005-03-22 | Altana Pharma Ag | Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo |
| GB2420297B (en) * | 2003-06-18 | 2006-11-15 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
| US8802139B2 (en) | 2003-06-26 | 2014-08-12 | Intellipharmaceutics Corp. | Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient |
| US20050147663A1 (en) * | 2003-07-17 | 2005-07-07 | Mohan Mailatur S. | Method of treatment for improved bioavailability |
| AU2004259226B2 (en) * | 2003-07-17 | 2009-09-24 | Dr. Reddy's Laboratories Ltd | Pharmaceutical compositions having a swellable coating |
| RU2375048C2 (ru) * | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| JP2007504261A (ja) * | 2003-09-03 | 2007-03-01 | エイジーアイ・セラピューティクス・リサーチ・リミテッド | プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示 |
| AU2004273958A1 (en) * | 2003-09-19 | 2005-03-31 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
| EP1670442A4 (en) * | 2003-09-19 | 2011-09-14 | Penwest Pharmaceuticals Co | DOSAGE FORMS WITH DELAYED RELEASE |
| TWI372066B (en) * | 2003-10-01 | 2012-09-11 | Wyeth Corp | Pantoprazole multiparticulate formulations |
| WO2005032554A1 (en) * | 2003-10-03 | 2005-04-14 | Astron Research Pvt. Ltd | A novel transmucosal delivery system |
| EP2270511A3 (en) * | 2003-10-24 | 2011-08-24 | Immunaid Pty Ltd | Method of therapy |
| US20070065513A1 (en) * | 2003-10-31 | 2007-03-22 | Avi Avramoff | Stable lansoprazole formulation |
| US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
| GB0330171D0 (en) * | 2003-12-30 | 2004-02-04 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
| US20050181052A1 (en) * | 2004-02-17 | 2005-08-18 | Patel Satishkumar A. | Lansoprazole microtablets |
| MXPA06009991A (es) * | 2004-03-03 | 2007-04-10 | Teva Pharma | Una composicion farmaceutica estable que comprende un farmaco labil acido. |
| US20070141137A1 (en) * | 2004-03-04 | 2007-06-21 | Naoki Nagahara | Stable capsule preparation |
| RU2381813C2 (ru) * | 2004-03-22 | 2010-02-20 | Зольвай Фармасьютиклз Гмбх | Пероральные фармацевтические композиции на основе продуктов, содержащих липазы, прежде всего панкреатин, и пав |
| GB0407312D0 (en) * | 2004-03-31 | 2004-05-05 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
| US8815916B2 (en) | 2004-05-25 | 2014-08-26 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| CA2566655C (en) * | 2004-05-25 | 2013-04-16 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| CA2469427A1 (en) * | 2004-06-01 | 2005-12-01 | Pharmascience Inc. | Dry mixed dosage form containing benzimidazole derivatives |
| JP2008502740A (ja) * | 2004-06-15 | 2008-01-31 | テバ ファーマシューティカル インダストリーズ リミティド | ベンズイミダゾール化合物の安定医薬製剤 |
| EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| US20050281876A1 (en) | 2004-06-18 | 2005-12-22 | Shun-Por Li | Solid dosage form for acid-labile active ingredient |
| US8394409B2 (en) | 2004-07-01 | 2013-03-12 | Intellipharmaceutics Corp. | Controlled extended drug release technology |
| US20080126195A1 (en) | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| US10624858B2 (en) | 2004-08-23 | 2020-04-21 | Intellipharmaceutics Corp | Controlled release composition using transition coating, and method of preparing same |
| CN101039698B (zh) * | 2004-09-20 | 2011-11-09 | Ltb4瑞典公司 | 稳定的白三烯b4(ltb4)药剂的药学配方 |
| WO2006067599A2 (en) | 2004-12-23 | 2006-06-29 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
| AU2006213439A1 (en) * | 2005-01-03 | 2006-08-17 | Lupin Limited | Pharmaceutical composition of acid labile substances |
| US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
| EP1845982A2 (en) * | 2005-02-02 | 2007-10-24 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions prepared by non-aqueous layering process |
| US20060210637A1 (en) * | 2005-03-17 | 2006-09-21 | Qpharma, Llc | Stable tablet dosage forms of proton pump inhibitors |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
| WO2006111853A2 (en) * | 2005-04-18 | 2006-10-26 | Aurobindo Pharma Limited | Stable solid dosage forms of acid labile drug |
| US7981908B2 (en) | 2005-05-11 | 2011-07-19 | Vecta, Ltd. | Compositions and methods for inhibiting gastric acid secretion |
| US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| US20070026071A1 (en) * | 2005-07-28 | 2007-02-01 | Qpharma, Llc | Magnesium salt proton pump inhibitor dosage forms |
| JP5140586B2 (ja) * | 2005-07-29 | 2013-02-06 | アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 滅菌パンクレアチン粉末の製法 |
| US9198871B2 (en) * | 2005-08-15 | 2015-12-01 | Abbott Products Gmbh | Delayed release pancreatin compositions |
| US11266607B2 (en) * | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
| DE602006012346D1 (de) * | 2005-08-15 | 2010-04-01 | Solvay Pharm Gmbh | Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel |
| WO2007041790A1 (en) * | 2005-10-14 | 2007-04-19 | Jon Pty Limited | Salts of proton pump inhibitors and process for preparing same |
| KR100591142B1 (ko) * | 2005-11-04 | 2006-06-20 | 지엘팜텍 주식회사 | 파록세틴을 활성물질로 함유하는 장용성 서방형 정제 |
| EP1785135A1 (en) * | 2005-11-10 | 2007-05-16 | Laboratorios Del Dr. Esteve, S.A. | New stabilized galenic formulations comprising lansoprazole and their preparation |
| AR057181A1 (es) * | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
| US8124779B2 (en) | 2005-12-05 | 2012-02-28 | Astrazeneca Ab | Process for the preparation of esomeprazole non-salt form |
| US10064828B1 (en) | 2005-12-23 | 2018-09-04 | Intellipharmaceutics Corp. | Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems |
| MY151470A (en) * | 2005-12-28 | 2014-05-30 | Takeda Pharmaceutical | Controlled release solid preparation |
| EP1965774A2 (en) * | 2005-12-30 | 2008-09-10 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| WO2007080601A1 (en) * | 2006-01-16 | 2007-07-19 | Jubilant Organosys Limited | Stable pharmaceutical formulation of an acid labile compound and process for preparing the same |
| US20070190145A1 (en) * | 2006-01-27 | 2007-08-16 | Eurand, Inc. | Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids |
| KR20140088230A (ko) * | 2006-01-27 | 2014-07-09 | 앱탈리스 파마테크, 인코포레이티드 | 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템 |
| US7776831B2 (en) | 2006-02-01 | 2010-08-17 | Weg Stuart L | Use of antifungal compositions to treat upper gastrointestinal conditions |
| WO2007112581A1 (en) | 2006-04-03 | 2007-10-11 | Isa Odidi | Controlled release delivery device comprising an organosol coat |
| EP2007362B1 (en) | 2006-04-04 | 2018-09-05 | KG Acquisition LLC | Oral dosage forms including an antiplatelet agent and an acid inhibitor |
| US10960077B2 (en) | 2006-05-12 | 2021-03-30 | Intellipharmaceutics Corp. | Abuse and alcohol resistant drug composition |
| US10072256B2 (en) * | 2006-05-22 | 2018-09-11 | Abbott Products Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| ITMI20061024A1 (it) * | 2006-05-25 | 2007-11-26 | Eurand Pharmaceuticals Ltd | Pellet a base di acido lipoico |
| US20100297226A1 (en) * | 2006-06-01 | 2010-11-25 | Dexcel Pharma Technologies Ltd. | Multiple unit pharmaceutical formulation |
| AR056062A1 (es) | 2006-06-05 | 2007-09-19 | Bago Sa Labor | Composicion farmaceutica antiacida en forma de polvo, preparacion farmaceutica que la comprende y proceso para su preparacion |
| CA2658804A1 (en) | 2006-07-25 | 2008-01-31 | Vecta Ltd. | Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with ppi |
| EP2068841B1 (en) | 2006-10-05 | 2018-09-26 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| SI2124556T1 (sl) | 2006-10-09 | 2015-01-30 | Charleston Laboratories, Inc. | Farmacevtske sestave |
| AU2007311493B2 (en) * | 2006-10-17 | 2013-01-31 | Ranbaxy Laboratories Limited | Multiple unit tablet compositions of benzimidazole compounds |
| WO2008057802A2 (en) | 2006-10-27 | 2008-05-15 | The Curators Of The University Of Missouri | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same |
| US8352042B2 (en) * | 2006-11-28 | 2013-01-08 | The Alfred E. Mann Foundation For Scientific Research | Remote controls and ambulatory medical systems including the same |
| US20110174855A1 (en) * | 2006-11-29 | 2011-07-21 | Yakima Products, Inc. | Vehicle top carriers |
| HUE046465T2 (hu) | 2006-12-22 | 2020-03-30 | Ironwood Pharmaceuticals Inc | Epesavat megkötõ anyagokat tartalmazó készítmények nyelõcsõ-rendellenességek kezelésére |
| US20080194307A1 (en) * | 2007-02-13 | 2008-08-14 | Jeff Sanger | Sports-based game of chance |
| US8221747B2 (en) * | 2007-02-20 | 2012-07-17 | Aptalis Pharma Limited | Stable pancreatic enzyme compositions |
| US20090117180A1 (en) * | 2007-02-20 | 2009-05-07 | Giovanni Ortenzi | Stable digestive enzyme compositions |
| JP5228359B2 (ja) * | 2007-04-12 | 2013-07-03 | ニプロ株式会社 | 主薬粒子及びその製造方法ならびに口腔内崩壊錠 |
| BRPI0721654B8 (pt) * | 2007-05-07 | 2022-07-05 | Evonik Roehm Gmbh | formas de dosagem sólida compreendendo um revestimento entérico com liberação acelerada do fármaco, seu método de fabricação e uso |
| WO2009012393A1 (en) * | 2007-07-18 | 2009-01-22 | The Curators Of The University Of Missouri | Pharmaceutical composition comprising a proton pump inhibitor and protein component |
| US8173158B2 (en) | 2007-10-12 | 2012-05-08 | Takeda Pharmaceuticals U.S.A., Inc. | Methods of treating gastrointestinal disorders independent of the intake of food |
| ITFI20070253A1 (it) * | 2007-11-09 | 2009-05-10 | Valpharma Internat S P A | Formulazioni farmaceutiche per la somministrazione di ipp. |
| US20090130063A1 (en) * | 2007-11-15 | 2009-05-21 | Solvay Pharmaceuticals Gmbh | Process for separating and determining the viral load in a pancreatin sample |
| US8124126B2 (en) | 2008-01-09 | 2012-02-28 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| CN101980700A (zh) | 2008-02-20 | 2011-02-23 | 密苏里大学董事会 | 包含奥美拉唑和兰索拉唑以及缓冲剂的组合的组合物及其使用方法 |
| US8911787B2 (en) | 2008-02-26 | 2014-12-16 | Ranbaxy Laboratories Limited | Stable oral benzimidazole compositions and process of preparation thereof |
| US10087493B2 (en) | 2008-03-07 | 2018-10-02 | Aptalis Pharma Canada Ulc | Method for detecting infectious parvovirus in pharmaceutical preparations |
| TWI519322B (zh) * | 2008-04-15 | 2016-02-01 | 愛戴爾製藥股份有限公司 | 包含弱鹼性藥物及控制釋放劑型之組合物 |
| US20090263475A1 (en) * | 2008-04-21 | 2009-10-22 | Nagaraju Manne | Dexlansoprazole compositions |
| WO2009137648A1 (en) * | 2008-05-09 | 2009-11-12 | Aptapharma, Inc. | Multilayer proton pump inhibitor tablets |
| US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
| AU2009267145A1 (en) * | 2008-06-30 | 2010-01-07 | Merck Sharp & Dohme Corp. | Solid dosage formulations of telcagepant potassium |
| AU2008359725A1 (en) * | 2008-07-24 | 2010-01-28 | Handa Pharmaceuticals, Llc | Stabilized atypical antipsychotic formulation |
| CA2733299A1 (en) * | 2008-08-11 | 2010-02-18 | Mepha Gmbh | Oral pharmaceutical formulation for omeprazole comprising a specific separation layer |
| DE102008045339A1 (de) | 2008-09-01 | 2010-03-04 | Stada Arzneimittel Ag | Pharmazeutisches Pellet |
| CA2736547C (en) * | 2008-09-09 | 2016-11-01 | Pozen Inc. | Method for delivering a pharmaceutical composition to patient in need thereof |
| CN102404990A (zh) | 2009-02-24 | 2012-04-04 | 里特制药股份有限公司 | 益生素制剂和使用方法 |
| WO2010122583A2 (en) | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
| ES2548508T3 (es) | 2009-05-27 | 2015-10-19 | Biotempus Limited | Métodos de tratamiento de enfermedades |
| AU2010263304A1 (en) | 2009-06-25 | 2012-02-02 | Astrazeneca Ab | Method for treating a patient at risk for developing an NSAID-associated ulcer |
| US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| EP2451274B1 (en) | 2009-07-08 | 2017-10-04 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
| JP2011037787A (ja) * | 2009-08-13 | 2011-02-24 | Kyorin Pharmaceutical Co Ltd | 塩基性薬物のｐＨに依存しない安定放出組成物 |
| WO2011025673A1 (en) * | 2009-08-26 | 2011-03-03 | Aptapharma, Inc. | Multilayer minitablets |
| EP2319504A1 (en) | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
| US20110189271A1 (en) * | 2010-02-02 | 2011-08-04 | Vishal Lad | Pharmaceutical formulations of acid-labile drugs |
| WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| WO2011138797A2 (en) | 2010-05-04 | 2011-11-10 | Cadila Healthcare Limited | Delayed release oral disintegrating pharmaceutical compositions of lansoprazole |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| EA029101B1 (ru) | 2010-10-01 | 2018-02-28 | Апталис Фарма Лимитид | Составы с низкой дозой панкрелипазы и кишечнорастворимым покрытием |
| DE102010052847A1 (de) * | 2010-11-29 | 2012-05-31 | Temmler Werke Gmbh | Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung |
| US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
| WO2012103411A2 (en) | 2011-01-28 | 2012-08-02 | Zx Pharma, Llc | Controlled-release melatonin composition and related methods |
| US8568776B2 (en) | 2011-02-11 | 2013-10-29 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
| US8808736B2 (en) | 2011-02-11 | 2014-08-19 | Zx Pharma, Llc | Enteric coated multiparticulate controlled release peppermint oil composition and related methods |
| US8911780B2 (en) | 2011-02-11 | 2014-12-16 | Zx Pharma, Llc | Multiparticulate L-menthol formulations and related methods |
| US9976171B2 (en) | 2011-08-08 | 2018-05-22 | Allergan Pharmaceuticals International Limited | Method for dissolution testing of solid compositions containing digestive enzymes |
| GB201117480D0 (en) | 2011-10-10 | 2011-11-23 | Palikaras George | Filter |
| EP2601947A1 (en) | 2011-12-05 | 2013-06-12 | Abo Bakr Mohammed Ali Al-Mehdar | Fixed-dose combination for treatment of helicobacter pylori associated diseases |
| UA115139C2 (uk) | 2011-12-28 | 2017-09-25 | Поузен Інк. | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту |
| KR102160388B1 (ko) | 2012-03-19 | 2020-09-28 | 버크 인스티튜트 포 리서치 온 에이징 | App 특이적 bace 억제제(asbi) 및 이의 용도 |
| WO2014025905A1 (en) | 2012-08-07 | 2014-02-13 | Buck Institute For Research On Aging | Multi-component formulation for improving neurological function |
| CN102940611B (zh) * | 2012-11-26 | 2017-02-22 | 康普药业股份有限公司 | 一种含有埃索美拉唑镁的肠溶片剂 |
| CN102961356A (zh) * | 2012-12-11 | 2013-03-13 | 山西云鹏制药有限公司 | 一种含奥美拉唑的蓝色肠溶片剂的制备方法 |
| WO2014113377A1 (en) | 2013-01-15 | 2014-07-24 | Ironwood Pharmaceuticals, Inc. | Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant |
| KR102220259B1 (ko) | 2013-02-12 | 2021-02-25 | 버크 인스티튜트 포 리서치 온 에이징 | Bace 매개 app 처리과정을 조절하는 히단토인 |
| JP5934835B2 (ja) * | 2013-03-08 | 2016-06-15 | 富士フイルム株式会社 | 腸溶性細粒及び医薬組成物 |
| RU2647462C2 (ru) * | 2013-04-23 | 2018-03-15 | ЗедЭкс ФАРМА, ЭлЭлСи | Композиция, состоящая из множества частиц, покрытых кишечнорастворимой оболочкой и имеющих белковую внутреннюю оболочку |
| ES2784227T3 (es) | 2013-08-09 | 2020-09-23 | Allergan Pharmaceuticals Int Ltd | Composición de enzimas digestivos adecuada para la administración entérica |
| EP3082777A4 (en) * | 2013-12-20 | 2017-06-21 | 9286-3620 Québec Inc. | Protein-based enteric coating for oral dosage forms |
| CN104586772A (zh) * | 2013-12-30 | 2015-05-06 | 四川迪康科技药业股份有限公司 | 质子泵抑制剂肠溶制剂及其包衣系统和制备方法 |
| CN104337788B (zh) * | 2013-12-30 | 2016-05-11 | 成都迪康药业有限公司 | 埃索美拉唑钠肠溶制剂及其制备方法 |
| CN104337789B (zh) * | 2013-12-30 | 2016-05-11 | 成都迪康药业有限公司 | 雷贝拉唑钠肠溶制剂及其制备方法 |
| KR101658275B1 (ko) | 2014-01-20 | 2016-09-20 | 대원제약주식회사 | 에스오메프라졸 함유 소형 의약정제 |
| WO2015153841A1 (en) | 2014-04-04 | 2015-10-08 | Ritter Pharmaceuticals, Inc. | Methods and compositions for microbiome alteration |
| AU2015275860A1 (en) | 2014-06-19 | 2016-11-03 | Aptalis Pharma Ltd. | Methods for removing viral contaminants from pancreatic extracts |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| CA2936746C (en) | 2014-10-31 | 2017-06-27 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| WO2016126625A1 (en) | 2015-02-03 | 2016-08-11 | Ironwood Pharmaceuticals, Inc. | Methods of treating upper gastrointestinal disorders in ppi refractory gerd |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| ES2944568T3 (es) * | 2015-07-17 | 2023-06-22 | Be Pharbel Mfg | Micropartículas multicapa de liberación de compuestos farmacéuticamente activos en forma de dosificación líquida |
| BE1024339B1 (fr) * | 2016-07-01 | 2018-01-29 | Be Pharbel Mfg Sa | Microparticules multicouches libérant un composé pharmaceutiquement actif dans une forme pharmaceutique liquide |
| EP3117824A1 (en) * | 2015-07-17 | 2017-01-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
| EP3380085B1 (de) * | 2015-11-27 | 2021-01-13 | Symrise AG | Orale zubereitungen mit omeprazol oder pantoprazol |
| EP4218739A3 (en) | 2016-01-08 | 2023-08-09 | The Regents of The University of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
| WO2017145146A1 (en) | 2016-02-25 | 2017-08-31 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| JP2019507181A (ja) | 2016-03-04 | 2019-03-14 | チャールストン ラボラトリーズ，インコーポレイテッド | 医薬組成物 |
| CN109563089B (zh) | 2016-05-12 | 2023-06-16 | 巴克老年研究所 | 促进app正常加工的化合物 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| EP3292862A1 (en) | 2016-09-07 | 2018-03-14 | Sandoz Ag | Omeprazole formulations |
| US11554114B2 (en) * | 2017-03-31 | 2023-01-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredients |
| CZ2017315A3 (cs) | 2017-06-02 | 2018-12-12 | Zentiva, K.S. | Dávkovací jednotka s PPI (inhibitory protonové pumpy) |
| EP3642206A4 (en) | 2017-06-23 | 2021-04-07 | The Regents of The University of California | IMPROVING THE CAPACITY OF GABA TO MODULATE IMMUNE RESPONSES |
| KR102227486B1 (ko) * | 2017-06-30 | 2021-03-12 | 롯데정밀화학 주식회사 | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 |
| CA3088630A1 (en) | 2017-12-15 | 2019-06-20 | Solarea Bio, Inc. | Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome |
| KR102006777B1 (ko) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
| KR102080023B1 (ko) * | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
| RU2694527C1 (ru) | 2018-02-06 | 2019-07-16 | Шмуэль Борис Левит | Комбинация для регенеративной терапии больных сахарным диабетом 1 типа |
| CA3111795A1 (en) | 2018-09-05 | 2020-03-12 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases |
| US11980647B2 (en) | 2018-09-05 | 2024-05-14 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| EA202191983A1 (ru) | 2019-01-22 | 2021-12-01 | Аеовиан Фармасьютикалз, Инк. | МОДУЛЯТОРЫ mTORC И ИХ ПРИМЕНЕНИЕ |
| WO2020257722A2 (en) | 2019-06-19 | 2020-12-24 | Solarea Bio, Inc. | Microbial compositions and methods for producing upgraded probiotic assemblages |
| TW202126301A (zh) * | 2019-10-04 | 2021-07-16 | 愛爾蘭商席歐拉斯製藥有限公司 | 小兒懸浮調配物 |
| WO2021115648A1 (en) | 2019-12-11 | 2021-06-17 | Evonik Operations Gmbh | Dosage form comprising an alkaline agent and an enteric coating layer |
| KR20220113698A (ko) | 2019-12-11 | 2022-08-16 | 에보닉 오퍼레이션스 게엠베하 | 질환을 치료 또는 예방하는데 사용하기 위한 투여 형태 |
| EP4072531A1 (en) * | 2019-12-11 | 2022-10-19 | Evonik Operations GmbH | Dosage form for use in treating or preventing of a disease |
| CN114569579B (zh) | 2020-12-02 | 2023-10-31 | 丽珠医药集团股份有限公司 | 肠溶微丸、其制备方法和包含它的制剂 |
| CN114569580B (zh) * | 2020-12-02 | 2024-03-01 | 丽珠医药集团股份有限公司 | 肠溶微丸、其制备方法和包含它的制剂 |
| ES2924573B2 (es) * | 2021-03-18 | 2024-04-24 | Aora Health S L | Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal |
| CN112919975B (zh) * | 2021-04-01 | 2022-02-11 | 山东爱福地生物股份有限公司 | 一种智能调控土壤酸碱度的有机肥的生产工艺 |
| WO2023092150A1 (en) | 2021-11-22 | 2023-05-25 | Solarea Bio, Inc. | Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause |
| US20230190834A1 (en) | 2021-12-21 | 2023-06-22 | Solarea Bio, Inc. | Immunomodulatory compositions comprising microbial entities |
| IL315304A (en) | 2022-03-04 | 2024-10-01 | Revagenix Inc | Broad-spectrum aminoglycoside antibiotics and their uses |
| WO2024075017A1 (en) | 2022-10-04 | 2024-04-11 | Zabirnyk Arsenii | Inhibition of aortic valve calcification |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0064283A2 (en) * | 1981-04-30 | 1982-11-10 | Syntex (U.S.A.) Inc. | Stabilization of 1-substituted imidazole derivatives in talc |
| JPS5920219A (ja) * | 1982-07-26 | 1984-02-01 | Shin Etsu Chem Co Ltd | 腸溶性コ−テイング製剤の製造方法 |
| JPS59167587A (ja) * | 1983-03-04 | 1984-09-21 | アクチエボラゲツト・ヘツスレ | オメプラゾ−ル化合物 |
| JPS6019715A (ja) * | 1983-07-12 | 1985-01-31 | Nisshin Flour Milling Co Ltd | 安定なイソカルボスチリル製剤 |
| JPS62277322A (ja) * | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2540979A (en) * | 1948-04-24 | 1951-02-06 | Smith Kline French Lab | Enteric coating |
| GB760403A (en) * | 1952-10-16 | 1956-10-31 | Abbott Lab | Improvements in or relating to enteric coatings |
| DE1204363B (de) * | 1963-09-10 | 1965-11-04 | Hoffmann La Roche | Verfahren zur Herstellung einer oralen Arzneizubereitung, die ihren Wirkstoff erst im Ileum abgibt |
| DE1617615A1 (de) * | 1966-05-03 | 1971-03-25 | Merck Patent Gmbh | Verfahren zur Herstellung von oral vertraeglichen festen Arzneimittelzubereitungen mit Resorptionsverzoegerung |
| GB1190387A (en) * | 1966-05-24 | 1970-05-06 | Green Cross Corp | Enteric Coated Medicaments |
| DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
| ZA743391B (en) * | 1974-05-28 | 1975-08-27 | A Warren | Therapeutic products |
| JPS5157813A (en) * | 1974-11-14 | 1976-05-20 | Sankyo Co | Ll dooba mataha sonojudotaiseizaino seiho |
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
| US4472409A (en) * | 1981-11-05 | 1984-09-18 | Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung | 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects |
| JPS58135806A (ja) * | 1982-02-08 | 1983-08-12 | Nippon Kayaku Co Ltd | 多層コ−チング製剤 |
| DE3233764C2 (de) * | 1982-09-11 | 1987-05-07 | R.P. Scherer GmbH, 6930 Eberbach | Verfahren zur Herstellung oraler Dosierungseinheiten |
| EP0153105B1 (en) * | 1984-02-10 | 1992-09-09 | Benzon Pharma A/S | Diffusion coated multiple-units dosage form |
| SE8404065D0 (sv) * | 1984-08-10 | 1984-08-10 | Haessle Ab | Novel biologically active compounds |
| US4685919A (en) * | 1985-03-14 | 1987-08-11 | Ngk Spark Plug Co., Ltd. | Artificial joint |
| CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
-
1986
- 1986-04-30 GB GB08610572A patent/GB2189698A/en not_active Withdrawn
-
1987
- 1987-04-01 ZA ZA872378A patent/ZA872378B/xx unknown
- 1987-04-15 SI SI8710681A patent/SI8710681A8/sl unknown
- 1987-04-15 YU YU68187A patent/YU46192B/sh unknown
- 1987-04-16 DE DE198787850127T patent/DE247983T1/de active Pending
- 1987-04-16 DE DE8787850127T patent/DE3783394T2/de not_active Ceased
- 1987-04-16 EP EP92107179A patent/EP0496437B1/en not_active Expired - Lifetime
- 1987-04-16 AT AT93201611T patent/ATE184482T1/de not_active IP Right Cessation
- 1987-04-16 ES ES93201611T patent/ES2135443T3/es not_active Expired - Lifetime
- 1987-04-16 AT AT87850127T patent/ATE84215T1/de not_active IP Right Cessation
- 1987-04-16 ES ES87850127T patent/ES2006457T3/es not_active Expired - Lifetime
- 1987-04-16 AT AT92107179T patent/ATE140387T1/de not_active IP Right Cessation
- 1987-04-16 EP EP93201611A patent/EP0567201B1/en not_active Revoked
- 1987-04-16 ES ES92107179T patent/ES2091971T3/es not_active Expired - Lifetime
- 1987-04-16 EP EP87850127A patent/EP0247983B1/en not_active Expired - Lifetime
- 1987-04-16 DE DE3751860T patent/DE3751860T2/de not_active Ceased
- 1987-04-20 US US07/040,491 patent/US4786505A/en not_active Expired - Lifetime
- 1987-04-27 NZ NZ220096A patent/NZ220096A/en unknown
- 1987-04-27 PH PH35184A patent/PH25701A/en unknown
- 1987-04-28 DK DK215887A patent/DK169988B1/da not_active IP Right Cessation
- 1987-04-28 DZ DZ870069A patent/DZ1077A1/fr active
- 1987-04-28 IE IE110787A patent/IE61416B1/en not_active IP Right Cessation
- 1987-04-28 IS IS3221A patent/IS1917B/is unknown
- 1987-04-29 NO NO871790A patent/NO174239C/no unknown
- 1987-04-29 PT PT84785A patent/PT84785B/pt unknown
- 1987-04-29 FI FI871913A patent/FI90393C/sv not_active IP Right Cessation
- 1987-04-29 KR KR1019870004132A patent/KR910004579B1/ko not_active IP Right Cessation
- 1987-04-29 PL PL1987265416A patent/PL151631B1/pl unknown
- 1987-04-29 CA CA000535899A patent/CA1292693C/en not_active Expired - Lifetime
- 1987-04-29 HU HU871948A patent/HU196708B/hu active IP Right Maintenance
- 1987-04-29 RU SU874202525A patent/RU1820837C/ru active
- 1987-04-29 DD DD87302262A patent/DD273197A5/de unknown
- 1987-04-30 AR AR307447A patent/AR240250A1/es active
- 1987-04-30 JP JP62108762A patent/JPS62258320A/ja active Granted
- 1987-04-30 CN CN87103284A patent/CN1020852C/zh not_active Expired - Lifetime
- 1987-06-18 IL IL82911A patent/IL82911A/xx not_active IP Right Cessation
-
1989
- 1989-06-22 GR GR89300058T patent/GR890300058T1/el unknown
-
1991
- 1991-12-20 JP JP3355985A patent/JP2740993B2/ja not_active Expired - Lifetime
-
1992
- 1992-04-24 RU SU925011683A patent/RU2095054C1/ru active
- 1992-10-02 HR HRP-681/87A patent/HRP920854B1/xx not_active IP Right Cessation
-
1993
- 1993-03-23 GR GR930400621T patent/GR3007434T3/el unknown
- 1993-06-28 LV LVP-93-694A patent/LV10357B/en unknown
- 1993-12-28 LT LTIP1683A patent/LT3699B/lt not_active IP Right Cessation
-
1994
- 1994-10-21 SG SG154294A patent/SG154294G/en unknown
- 1994-12-01 HK HK135294A patent/HK135294A/xx not_active IP Right Cessation
-
1995
- 1995-10-20 CY CY181095A patent/CY1810A/xx unknown
-
1996
- 1996-07-17 LV LV960264A patent/LV5760B4/xx unknown
- 1996-08-07 GR GR960402099T patent/GR3020734T3/el unknown
-
1997
- 1997-04-24 HK HK52897A patent/HK52897A/xx not_active IP Right Cessation
-
1999
- 1999-12-10 GR GR990403191T patent/GR3032101T3/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0064283A2 (en) * | 1981-04-30 | 1982-11-10 | Syntex (U.S.A.) Inc. | Stabilization of 1-substituted imidazole derivatives in talc |
| JPS5920219A (ja) * | 1982-07-26 | 1984-02-01 | Shin Etsu Chem Co Ltd | 腸溶性コ−テイング製剤の製造方法 |
| JPS59167587A (ja) * | 1983-03-04 | 1984-09-21 | アクチエボラゲツト・ヘツスレ | オメプラゾ−ル化合物 |
| JPS6019715A (ja) * | 1983-07-12 | 1985-01-31 | Nisshin Flour Milling Co Ltd | 安定なイソカルボスチリル製剤 |
| JPS62277322A (ja) * | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
Cited By (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01290628A (ja) * | 1988-05-18 | 1989-11-22 | Eisai Co Ltd | 酸不安定化合物の内服用製剤 |
| JPH0222225A (ja) * | 1988-07-11 | 1990-01-25 | Eisai Co Ltd | 胃酸分泌抑制剤含有固型製剤 |
| JPH04288015A (ja) * | 1990-10-11 | 1992-10-13 | Merck & Co Inc | 消化性潰瘍の治療 |
| JPH072648A (ja) * | 1993-04-23 | 1995-01-06 | Ciba Geigy Ag | 徐放性ドラッグデリバリーデバイス |
| JP2006342187A (ja) * | 1993-04-23 | 2006-12-21 | Novartis Ag | 徐放性ドラッグデリバリーデバイス |
| USRE45198E1 (en) | 1996-01-04 | 2014-10-14 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6780882B2 (en) | 1996-01-04 | 2004-08-24 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| JPH11501951A (ja) * | 1996-01-08 | 1999-02-16 | アストラ・アクチエボラーグ | プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形 |
| JP4638561B2 (ja) * | 1996-01-08 | 2011-02-23 | アストラゼネカ・アクチエボラーグ | プロトンポンプ抑制剤を含有するマルチプルユニットの沸騰剤形 |
| JP4641075B2 (ja) * | 1996-06-28 | 2011-03-02 | アストラゼネカ・アクチエボラーグ | ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法 |
| JP2000514051A (ja) * | 1996-06-28 | 2000-10-24 | クリンゲ ファーマ ジーエムビーエイチ | ベンズイミダゾール誘導体を活性成分とする経口投与用の安定な薬剤形およびその製造方法 |
| JP2002500665A (ja) * | 1997-05-28 | 2002-01-08 | アストラ・アクチエボラーグ | オメプラゾール製剤 |
| JP4649001B2 (ja) * | 1997-05-28 | 2011-03-09 | アストラゼネカ・アクチエボラーグ | オメプラゾール製剤 |
| JP2001525366A (ja) * | 1997-12-08 | 2001-12-11 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | 酸不安定な活性化合物を含有する新規の投与形 |
| EP2263660A2 (en) | 1998-05-18 | 2010-12-22 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| EP1736144A2 (en) | 1998-05-18 | 2006-12-27 | Takeda Pharmaceutical Company Limited | Orally disintegrable tablets |
| US7220762B1 (en) | 1999-10-20 | 2007-05-22 | Eisai R&D Management Co., Ltd. | Methods for stabilizing benzimidazole compounds |
| JP2003516342A (ja) * | 1999-12-09 | 2003-05-13 | ラティオファルム ゲー・エム・ベー・ハー | ベンズイミダゾールを含む安定な医薬品およびその製造方法 |
| JP2002234842A (ja) * | 2001-02-09 | 2002-08-23 | Kyowa Yakuhin Kogyo Kk | 内服腸溶性製剤 |
| JP2005521693A (ja) * | 2002-03-05 | 2005-07-21 | アストラゼネカ・アクチエボラーグ | オメプラゾール及びエソメプラゾールのアルキルアンモニウム塩 |
| US8697094B2 (en) | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| US9265730B2 (en) | 2002-10-16 | 2016-02-23 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| JP2015145405A (ja) * | 2002-10-16 | 2015-08-13 | 武田薬品工業株式会社 | 安定な固形製剤 |
| JP2010180225A (ja) * | 2002-10-16 | 2010-08-19 | Takeda Chem Ind Ltd | 安定な固形製剤 |
| JP2004155773A (ja) * | 2002-10-16 | 2004-06-03 | Takeda Chem Ind Ltd | 安定な固形製剤 |
| JP2013151525A (ja) * | 2002-10-16 | 2013-08-08 | Takeda Chem Ind Ltd | 安定な固形製剤 |
| US8697097B2 (en) | 2002-10-16 | 2014-04-15 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| JP2006528198A (ja) * | 2003-07-23 | 2006-12-14 | ザ キュレイターズ オブ ザ ユニバーシティー オブ ミズーリ | 酸不安定な医薬組成物の即時放出製剤 |
| JP2007517038A (ja) * | 2003-12-30 | 2007-06-28 | ドクター レディズ ラボラトリーズ リミテッド | 薬学的組成物 |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| JP2009504709A (ja) * | 2005-08-15 | 2009-02-05 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 酸に不安定な薬剤のための制御放出性医薬組成物 |
| WO2007074856A1 (ja) | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | 口腔内崩壊性固形製剤の製造法 |
| JP2012505884A (ja) * | 2008-10-20 | 2012-03-08 | ケージー アクキュイシチオン エルエルシー | 抗血小板薬と腸溶性コーティング酸阻害剤とを含む経口剤形 |
| JP2015180670A (ja) * | 2008-10-20 | 2015-10-15 | ケージー アクキュイシチオン エルエルシー | 抗血小板薬と腸溶性コーティング酸阻害剤とを含む経口剤形 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS62258320A (ja) | 内服用新規医薬製剤 | |
| EP0502556B1 (en) | Use of specific core material and layers to obtain pharmaceutical formulations stable to discolouration of acid labile compounds | |
| CZ379596A3 (en) | Novel oral pharmaceutical preparation containing omeprazol magnesium salt | |
| CN100431526C (zh) | 一种酸敏感型药物的快速崩解片剂 | |
| JP2000212085A (ja) | オメプラゾ―ル又はその他類似物を含有する高安定性経口医薬製剤及びその製法 | |
| WO2007054565A2 (en) | New stabilized galenic formulations comprising lansoprazole and their preparation | |
| WO2003077829A2 (en) | Process for preparation of a pharmaceutical composition containing acid labile compounds | |
| HRP920855A2 (en) | Pharmaceutical formulations of acid labile substances for oral use | |
| IL139894A (en) | Stable benzimidazole composition and a method for producing it |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071001 Year of fee payment: 14 |